Supplementary material 2
Follow-up duration, doses and regimens of reported patients after switch to SC C1INH LTP

Follow-up period (weeks)

Patient | 0 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80
--- | --- | --- | --- | --- | --- | --- | --- | --- | ---
1 | 65 | | | | | | | | |
2 | 40 | | | | | | | | |
3 | 53 | 65 | | | | | | | |
4 | 52 | | | | | | | | |
5 | 63 | | | | | | | | |
6 | 53 | | | | | | | | |
7 | 62 | | | | | | | | |
8 | 65 | | | | | | | | |
9 | 55 | | | | | | | | |
10 | 27 | 55 | | | | | | | |
11 | 21 | 17 | | | | | | | |
12 | 53 | 65 | | | | | | | |
13 | 40 | | | | | | | | |
14 | 52 | | | | | | | | |
15 | 52 | | | | | | | | |
16 | | 43 | | | | | | | |
17 | | 58 | | | | | | | |
18 | 12 | | | | | | | | |
19 | | 60 | | | | | | | |
20 | | | | | | | | | |
21 | | | | | | | | | |
22 | 15 | | | | | | | | |

1500 IU biw
2000 IU qw
2000 IU biw
2000 IU q3d
2000 IU tiw

biw, twice a week; qw, once a week; q3d, every 3 days; tiw, three times a week